BMAC – Biopharmaceutical Manufacturer's Advisory Council
An initiative by leading Biopharmaceutical companies in the world to establish Singapore as the country of choice for global biomedical sciences manufacturing.
Our vaccines facility at Tuas is a key manufacturing site within our global network supplying the active ingredients used to make multiple paediatric vaccines. To date, the site has played a key role in producing more than 800 million vaccines for serious childhood invasive diseases which include pneumonia and meningitis.
Pfizer Inc. today announced the extension of the company’s highly automated Active Pharmaceutical Ingredient (API) manufacturing facility in Tuas Biomedical Park, Singapore. The official opening
When he was a child, Mr Shaji Alias watched a family member struggle with asthma and saw the difference that one of GSK’s medicines made.
Every parent of a newborn knows the toll of sleepless nights, and Mr Lam Wain Sion is no exception. However, thanks to the 16 weeks